US4447545A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Bladder cancer detection
Assignee: Beth Israel Deaconess Medical Center
•
Filing: 1982-06-15
•
Granted: 1984-05-08
•
Expires: 2002-06-15
Abstract
Abstract Disclosed is a technique for screening populations to detect potential bladder cancer patients. The screening test is based on a discovered correlation between the respective ratios of C-reactive protein to total protein in urine and serum and the incidence of bladder cancer.
Inventors
- 👤 Sally R. DeFazio
- 👤 James J. Gozzo
- 👤 Anthony P. Monaco
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 04:03
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/68; G01N33/6893; G01N33/53; G01N33/575; G01N33/57525; G01N33/5754; G01N2800/00; G01N2800/34; Y; Y10; Y10S; Y10S435/00; Y10S435/967; Y10S436/00; Y10S436/804; Y10S436/811; Y10S436/813; Y10S436/815
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
131 words
A method for screening a patient for the presence of a bladder carcinoma, said method comprising the steps of: (A) assaying for the ratio of C-reactive protein to total protein in a sample of the urine of said patient; (B) assaying for the ratio of C-reactive protein to total protein in a sample of the serum of said patient; and (C) comparing the ratio determined by assay in step A to the ratio determined by assay in step B, whereby (i) a finding of the absence of C-reactive protein in said urine sample is indicative of the absence of a bladder carcinoma; and (ii) a finding that the ratio determined in step A is greater than the ratio determined in step B is indicative of the presence of a bladder carcinoma.
Claim 2
Independent Claim
131 words
A method for screening a patient for the presence of a bladder carcinoma, said method comprising the steps of: (A) assaying for the ratio of C-reactive protein to total protein in a sample of the urine of said patient; (B) assaying for the ratio of C-reactive protein to total protein in a sample of the serum of said patient; and (C) comparing the ratio determined by assay in step A to the ratio determined by assay in step B, whereby (i) a finding of the absence of C-reactive protein in said urine sample is indicative of the absence of a bladder carcinoma; and (ii) a finding that the ratio determined in step A is greater than the ratio determined in step B is indicative of the presence of a bladder carcinoma.
Claim 3
Dependent Claim
57 words
The method of claim 1 wherein the ratios determined in steps A and B are determined by a method comprising the steps of: (1) testing the sample to determine the total protein concentration; (2) assaying the sample to determine the C-reactive protein concentration; and (3) dividing the results of step 2 by the results of step 1.
Claim 4
Dependent Claim
25 words
The method of claim 2 wherein the assaying of the sample comprises an assay from a group consisting of radioimmunoassays, chemical immunoassays, and enzyme immunoassays.
Claim 5
Dependent Claim
154 words
The method of claim 3 wherein the assaying of the sample is conducted by a process comprising the steps of: (a) incubating a portion of said sample with an antibody complementary to C-reactive protein immobilized on an insoluble support under conditions to form an antigen-antibody bond between said immobilized antibody and said C-reactive protein; (b) washing the insoluble support to remove unbound components from the reactive system of step a; (c) incubating the support resulting from step b with a reagent comprising said antibody tagged with a detectable moiety under conditions to form an antigen-antibody bond between said tagged antibody and said C-reactive protein bound to said insoluble support; (d) washing the insoluble support to remove unbound components from the reaction system of step c; (e) assaying the support resulting from step d for the presence of said detectable moiety; and (f) comparing the results of the assay of step e to a standard.
Claim 6
Dependent Claim
16 words
The process of claim 4 wherein said detectable moiety is a moiety detectable by chemical means.
Claim 7
Dependent Claim
13 words
The process of claim 4 wherein said detectable moiety includes a radioactive atom.
Claim 8
Dependent Claim
21 words
The process of claim 4 wherein said detectable moiety is a moiety having a high binding affinity for an enzyme conjugate.
Claim 9
Dependent Claim
10 words
The process of claim 7 wherein said moiety is biotin.
Claim 10
Dependent Claim
12 words
The process of claim 4 wherein said detectable moiety comprises an enzyme.
Claim 11
Dependent Claim
12 words
The process of claim 4 wherein said standard comprises a standard curve.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-05-08 | 1987-11-07 | 1988-05-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-05-08 | 1991-11-07 | 1992-05-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-05-08 | 1995-11-07 | 1996-05-08 | $7700.00 | Window Closed / Lapsed |